Kiniksa reports 62% growth in ARCALYST revenue to $677.5 million

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported ARCALYST net product revenue of $677.5 million for 2025, representing approximately 62% year-over-year growth compared to $417.0 million in 2024, according to unaudited figures disclosed in a company statement.

The biopharmaceutical company projects ARCALYST net product revenue of $900 million to $920 million for 2026. As of the end of 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively receiving ARCALYST treatment for recurrent pericarditis.

ARCALYST, a weekly subcutaneous injection that blocks IL-1α and IL-1β signaling, is approved by the FDA for treating recurrent pericarditis and other conditions. The company reported that more than 4,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis since launch, with average treatment duration approaching three years.

Kiniksa's cash position increased by $170.4 million in 2025 to $414.1 million as of December 31, with no debt. The company expects to remain cash flow positive on an annual basis under its current operating plan.

The company is advancing KPL-387, a monoclonal antibody IL-1 receptor antagonist, in a Phase 2/3 clinical trial for recurrent pericarditis. Data from the dose-focusing portion is expected in the second half of 2026. KPL-387 received FDA Orphan Drug Designation for pericarditis treatment in October 2025.

Kiniksa plans to initiate a Phase 1 first-in-human trial for KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist designed for quarterly subcutaneous dosing, by the end of 2026.

Chief Executive Officer Sanj K. Patel stated that IL-1α and IL-1β inhibition with ARCALYST is becoming the preferred second-line treatment for patients with recurrent pericarditis.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• EquipmentShare disputes Blue Orca Capital short-seller report
• RiverNorth Opportunities Fund raises $35.2M in rights offering